It has been demonstrated that immunotherapies, targeting PD-1 pathway, have revolutionized the treatment landscape of different cancers, including Merkel cell carcinoma (MCC), melanoma, head and neck squamous cell carcinoma (HNSCC), and non-small-cell lung cancer (NSCLC) [34]. Here, PDCD1 is linked to non-small cell lung carcinoma.